NASDAQ:GH - Guardant Health Stock Price, Forecast & News

Guardant Health's stock was trading at $62.95 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GH shares have increased by 10.6% and is now trading at $69.60. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Guardant Health.

Guardant Health is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Guardant Health.

Guardant Health Inc (NASDAQ:GH) issued its quarterly earnings results on Monday, February, 24th. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The firm earned $62.90 million during the quarter, compared to analyst estimates of $54.87 million. Guardant Health had a negative return on equity of 10.02% and a negative net margin of 33.84%. Guardant Health's quarterly revenue was up 91.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.30) EPS. View Guardant Health's earnings history.

Guardant Health issued an update on its FY 2020 After-Hours earnings guidance on Monday, February, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $275-285 million, compared to the consensus revenue estimate of $273.13 million.

7 analysts have issued 12 month price objectives for Guardant Health's stock. Their forecasts range from $84.00 to $135.00. On average, they expect Guardant Health's share price to reach $109.50 in the next twelve months. This suggests a possible upside of 57.3% from the stock's current price. View analysts' price targets for Guardant Health.

Headlines about GH stock have been trending very negative this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Guardant Health earned a news impact score of -3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutGuardant Health.

Guardant Health saw a decline in short interest in March. As of March 13th, there was short interest totaling 4,136,700 shares, a decline of 10.3% from the February 27th total of 4,610,000 shares. Based on an average daily trading volume, of 1,783,100 shares, the short-interest ratio is currently 2.3 days. Currently, 7.7% of the company's stock are short sold. View Guardant Health's Current Options Chain.

Some companies that are related to Guardant Health include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), Veracyte (VCYT), CareDx (CDNA), Castle Biosciences (CSTL), RadNet (RDNT), Centogene (CNTG), Fulgent Genetics (FLGT), Personalis (PSNL), DermTech (DMTK), Enzo Biochem (ENZ) and Anpac Bio-Medical Science (ANPC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Alibaba Group (BABA), Twilio (TWLO), Trade Desk (TTD), Okta (OKTA), Micron Technology (MU), Paypal (PYPL), Alteryx (AYX), Roku (ROKU) and salesforce.com (CRM).

(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GH stock can currently be purchased for approximately $69.60.

Guardant Health has a market capitalization of $6.57 billion and generates $214.38 million in revenue each year. The company earns $-75,650,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Guardant Health employs 454 workers across the globe. View additional information about Guardant Health.

The official website for Guardant Health is http://www.guardanthealth.com/.

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887.